TrialLancet (London, England)2020

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Pedro M Folegatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.